Trial Profile
A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Sequential Therapy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Romosozumab (Primary) ; Alendronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms PILLAR
- Sponsors Amgen
- 13 Jul 2017 New trial record